New drugs may cause toxicity or damage to various organs and tissues, and such toxic effects can be detected early using corresponding 2D cell-based drug screening models. Before clinical trials or market approval, new drugs must undergo a series of preclinical toxicity assessments to provide safety information.
CellBall Biomedical’s professional team, leveraging years of expertise, customizes drug screening programs according to clients’ research needs and objectives. This includes the design of screening criteria, reagent selection, and experimental planning, as well as professional data analysis to interpret results in detail and generate comprehensive reports, supporting further research and drug efficacy evaluation.
